OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
The clinical efficacy of B cell depleting therapies (BCDT) highlights the pathogenic potential of B cells in inflammatory diseases such as RA. We have recently identified a pathogenic B cell subset that is enriched both in the joints of patients with RA and in the inflamed mucosa. We are currently exploring their antigen specificity, gene expression profile and their functional role in mucosal and joint inflammation.
——
Dr Dagmar Scheel-Toellner:
2015- Reader in Translational Inflammation Research. University of Birmingham.
2010-2015 Senior Research Fellow (HEFCE), University of Birmingham.
2010-2011 Arthritis Research UK Career Progression Fellow. University of Birmingham.
2004-2009 Arthritis Research UK Career Development Fellow, University of Birmingham.
2003 Fellow of the Higher Education Academy.
1994-2004 Postdoctoral Research Fellow, with Prof. Mike Salmon and Prof. Janet Lord. University of Birmingham.
1990-1994 PhD student at the Forschungszentrum Borstel, Germany. Advisor: Prof. Johannes Gerdes. PhD in Immunology awarded “summa cum laude”.
1989 BSc Pharmacy, registered pharmacist, Christian Albrechts Universität, Kiel, Germany.
